What's happened
The NHS has approved capivasertib, a new drug for advanced HR-positive HER2-negative breast cancer, benefiting up to 3,000 women annually. Meanwhile, Hutchmed received approval in China for tazemetostat, targeting follicular lymphoma patients with specific mutations. Both approvals mark significant advancements in cancer treatment options.
What's behind the headline?
Capivasertib Approval
- The approval of capivasertib by NICE is a pivotal moment for breast cancer treatment in the UK, providing a new option for patients with limited alternatives.
- This drug targets specific genetic mutations, which are prevalent in nearly half of HR-positive HER2-negative breast cancer cases, potentially extending survival and improving quality of life.
Tazemetostat's Impact
- Hutchmed's approval for tazemetostat in China highlights the growing focus on personalized medicine in oncology, particularly for patients with the EZH2 mutation.
- The company plans to expand its research to solid tumors, indicating a broader application of this treatment approach.
Broader Implications
- Both approvals reflect a trend towards targeted therapies in cancer treatment, emphasizing the importance of genetic testing to identify suitable candidates for these innovative drugs.
- As healthcare systems adapt to these advancements, the need for efficient testing and treatment protocols will become increasingly critical.
What the papers say
The Guardian reported that capivasertib's approval is a 'gamechanging' moment for thousands of women with advanced breast cancer, emphasizing the drug's ability to delay chemotherapy needs. The Independent highlighted the significance of this approval, noting that it could provide patients with precious extra time with their families. Meanwhile, the South China Morning Post detailed Hutchmed's approval for tazemetostat, marking a significant step in addressing the needs of follicular lymphoma patients in China. The article noted that this drug is the first of its kind approved in the country, showcasing Hutchmed's commitment to expanding treatment options for blood cancers.
How we got here
Capivasertib, developed by AstraZeneca, has been recognized for its ability to slow cancer progression in patients with specific genetic mutations. Tazemetostat, approved by China's NMPA, is the first EZH2 inhibitor for follicular lymphoma, addressing a significant patient population in China.
Go deeper
- What are the side effects of capivasertib?
- How does tazemetostat work for follicular lymphoma?
- What other cancer treatments are in development?
Common question
-
What are the latest cancer treatments approved in the UK?
Recent advancements in cancer treatment have brought hope to many patients. The NHS has approved two groundbreaking therapies: capivasertib for advanced breast cancer and erdafitinib for FGFR-altered urothelial cancer. These approvals mark a significant step forward in personalized cancer care, raising questions about their mechanisms, effectiveness, and potential side effects.
More on these topics
-
The United Kingdom of Great Britain and Northern Ireland, commonly known as the United Kingdom or Britain, is a sovereign country located off the northwestern coast of the European mainland.
-
AstraZeneca PLC is a British-Swedish multinational pharmaceutical and biopharmaceutical company with its global headquarters in Cambridge, England. Its R&D is concentrated in Cambridge, England, Mölndal in Sweden and North America.
-
Capivasertib, sold under the brand name Truqap, is an anti-cancer medication used for the treatment of breast cancer. It is taken by mouth.
The most common adverse reactions include diarrhea, cutaneous adverse reactions, increased random glucose, decrease
-
The National Institute for Health and Care Excellence is an executive non-departmental public body of the Department of Health in England, which publishes guidelines in four areas:
-
The United States of America, commonly known as the United States or America, is a country mostly located in central North America, between Canada and Mexico.